Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and



Novartis highlights key data in patients with hematologic diseases and breast
             cancer with more than 140 abstracts at ASH and SABCS

-- Long-term follow-up data from Jakavi® Phase III trials in patients with the
debilitating blood cancer, myelofibrosis

-- Updated Phase III data in patients with Ph+ CML who switched to Tasigna®
after long-term treatment with Gleevec® to achieve a deeper molecular response

-- Pipeline updates on multiple targeted compounds across blood cancers
including PKC412, LBH589 and the investigational immunotherapy CTL019
(CART-19)

-- Abstracts at SABCS highlight ongoing commitment to advanced breast cancer
and PI3K/mTOR inhibitor research including Afinitor®, BYL719 and BKM120

PR Newswire

EAST HANOVER, N.J., Nov. 28, 2012

EAST HANOVER, N.J., Nov. 28, 2012 /PRNewswire/ -- Novartis will highlight more
than 140 presentations on key data from its extensive oncology portfolio at
the leading year-end scientific meetings devoted to hematology and breast
cancer, demonstrating continued innovation in research and development efforts
to advance the care of patients with cancer and rare diseases.

The American Society of Hematology (ASH) annual meeting in Atlanta, held
December 8-11, will feature significant data across hematologic diseases
including two-year follow-up data from Phase III trials of Jakavi^®
(ruxolitinib) in patients treated with Jakavi for myelofibrosis and data
evaluating molecular response following treatment with Tasigna^® (nilotinib)
in patients with Philadelphia chromosome-positive chronic myeloid leukemia
(Ph+ CML) compared with Gleevec^® (imatinib mesylate)^* tablets therapy. In
addition, updated data on Exjade^® (deferasirox) in non-transfusion-dependent
thalassemia (NTDT), as well as new data on the removal of cardiac iron in
β-thalassemia major, will be presented.

Several studies of novel pipeline compounds will also be presented, including
additional Phase I/II findings extending proof-of-concept data for the
investigational therapy CTL019 (formerly known as CART-19)^† in patients with
chronic lymphocytic leukemia (CLL) and relapsed refractory acute lymphoblastic
leukemia (ALL)^1.

"For more than a decade, Novartis Oncology has discovered critical medicines
for cancer patients by following the science," said Herve Hoppenot, President,
Novartis Oncology. "The presentations at this year's annual meetings show that
our research and development pipeline has never been stronger, and we expect
new breakthroughs that could lead to even more innovative therapies for
patients."

The CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), held December 4-8,
will showcase studies exploring therapy with the mTOR inhibitor Afinitor^®
(everolimus) and the investigational PI3K inhibitors BYL719 and BKM120 in
patients with hormone receptor-positive (HR+), HER2/neu-negative (HER2-)
advanced breast cancer^2.

"Novartis is committed to helping fulfill the large unmet treatment need for
patients with advanced breast cancer, and we are continuing to investigate the
potential benefits and utility of Afinitor in this population," said
Alessandro Riva, Global Head, Oncology Development & Medical Affairs, Novartis
Oncology. "The company will also showcase promising results from our pipeline
of PI3K/mTOR inhibitors highlighting our commitment to ongoing exploration of
compounds that impact key disease pathways."

Highlights at ASH include:

  o Jakavi (ruxolitinib) – Long-term safety, efficacy and survival findings
    from COMFORT-II (COntrolled MyeloFibrosis Study With ORal JAK Inhibitor
    Treatment), a Phase III study comparing ruxolitinib with best available
    therapy for the treatment of myelofibrosis (ASH abstract #801; December
    10, 6:45 PM EST). Long-term outcome of ruxolitinib treatment in patients
    with myelofibrosis: durable reductions in spleen volume, improvements in
    quality of life and overall survival advantage in COMFORT-I (ASH abstract
    #800; December 10, 6:30 PM EST). 
  o Tasigna (nilotinib) – Two-year follow-up results from Evaluating Nilotinib
    Efficacy and Safety in Clinical Trials – Complete Molecular Response
    (ENESTcmr), evaluating sustained deeper molecular response following a
    switch to Tasigna in patients with Ph+ CML in chronic phase who still had
    evidence of residual disease after two or more years of Gleevec therapy
    (ASH abstract #694; December 10, 5:15 PM EST). Long-term landmark data
    from Evaluating Nilotinib Efficacy and Safety in Clinical Trials – Newly
    Diagnosed Patients (ENESTnd), correlating early molecular response and
    outcome of patients with Ph+ CML in chronic phase (ASH abstract #167;
    December 9, 5:30 PM EST). Four-year update from ENESTnd evaluating
    superiority of Tasigna vs. Gleevec in patients with newly diagnosed Ph+
    CML in chronic phase (ASH abstract #1676; December 8, 5:30 PM EST).
  o Exjade (deferasirox) – Two-year update to THALASSA, the first randomized,
    placebo-controlled study evaluating reduction of liver iron concentration
    and serum ferritin in patients with NTDT syndromes after treatment with
    deferasirox oral iron chelation therapy (ASH abstract #3258; December 10,
    6:00 PM EST). First data from CORDELIA, the first head-to-head
    multicenter, randomized, open-label trial evaluating deferasirox compared
    with deferoxamine for the removal of cardiac iron in patients with
    β-thalassemia major and iron overload (ASH abstract #2124; December 9,
    6:00 PM EST).
  o CTL019 (CART-19) – Outcomes and extended follow-up from a Phase I/II study
    in patients with advanced, refractory and high-risk CLL and relapsed
    refractory ALL treated with CART-19 cells (ASH abstract #717; December 10,
    5:00 PM EST).
  o PKC412 (midostaurin) – First presentation from the pivotal Phase II study
    of PKC412 in patients with advanced systemic mastocytosis and mast cell
    leukemia (ASH abstract #799; December 10, 6:15 PM EST).
  o LBH589 (panobinostat) – Updated results from PANORAMA-2 (PANobinostat ORAl
    in Multiple myelomA) Phase II study of LBH589 in combination with
    bortezomib (BTZ) and dexamethasone in patients with relapsed and
    BTZ-refractory multiple myeloma (ASH abstract #1852; December 8, 5:30 PM
    EST).

Highlights at SABCS include:

  o Afinitor (everolimus) – New data from a Phase II clinical trial evaluating
    Afinitor (everolimus) in combination with fulvestrant in postmenopausal
    women with HR+ advanced breast cancer who progressed on a previous
    endocrine therapy (SABCS abstract #P2-14-05; December 6, 7:00 AM CST) and
    an additional Phase II study evaluating the potential efficacy of Afinitor
    in combination with letrozole (SABCS abstract #P5-20-06; December 7, 5:00
    PM CST). Final progression-free survival analysis of BOLERO-2 Phase III
    trial of Afinitor plus exemestane for postmenopausal women with HR+/HER2-
    advanced breast cancer after failure of letrozole or anastrazole (SABCS
    abstract #P6-04-02; December 8, 7:00 AM CST).
  o BYL719 – Preliminary results from a Phase I study of BYL719 in patients
    with PIK3CA mutant ER+ metastatic breast cancer (SABCS abstract #P6-10-07;
    December 8, 7:00 AM CST).
  o BKM120 – Abstract highlighting trial in progress BELLE-3 Phase III
    randomized study of PI3K inhibitor BKM120 in combination with fulvestrant
    in postmenopausal women with HR+/HER2- advanced breast cancer whose
    disease has progressed after treatment with an aromatase inhibitor and on
    or after an mTOR inhibitor (SABCS abstract #OT2-3-08; December 6, 5:00 PM
    CST).
  o LBH589 (panobinostat) – Pre-clinical data explores the potential utility
    of HDAC inhibition in triple-negative breast cancer alone and in
    combination with other agents (SABCS abstract #S3-7; December 6, 9:30 AM
    CST).

About Jakavi

Jakavi^® (INC424, ruxolitinib) is an oral inhibitor of the JAK 1 and JAK 2
tyrosine kinases^3 and was approved by the European Commission in August 2012
for the treatment of disease-related splenomegaly or symptoms in adult
patients with primary myelofibrosis (also known as chronic idiopathic
myelofibrosis), post-polycythemia vera myelofibrosis or post-essential
thrombocythemia myelofibrosis. Jakavi is available in more than 30 countries
including the European Union member states and Canada, with additional global
regulatory filings underway.

Novartis licensed INC424 (ruxolitinib) from Incyte Corporation for development
and commercialization outside the US. Both the European Commission and the US
Food and Drug Administration (FDA) granted INC424 (ruxolitinib) orphan drug
status for myelofibrosis. Jakavi is marketed in the United States by Incyte
Corporation under the name Jakafi^® for the treatment of patients with
intermediate or high-risk myelofibrosis.

Jakavi is a registered trademark of Novartis AG in countries outside the
United States. Jakafi is a registered trademark of Incyte Corporation.

Jakavi^® Important Safety Information

Jakavi^® can cause serious side effects, including a decrease in blood cell
count and infections. Complete blood count monitoring is recommended. Dose
reduction or interruption may be required in patients with severe hepatic or
renal impairment or in patients developing hematologic adverse reactions such
as thrombocytopenia, anemia and neutropenia. Dose reductions are also
recommended when Jakavi is co-administered with strong CYP3A4 inhibitors or
fluconazole. Use of Jakavi during pregnancy is not recommended and women
should avoid becoming pregnant during Jakavi therapy. Women taking Jakavi
should not breast feed.

The most common adverse drug reactions, occurring at any level of severity,
(incidence >10%) are urinary tract infections, anemia, thrombocytopenia,
neutropenia, hypercholesterolaemia, dizziness, headache, alanine
aminotransaminase increased, asparte aminotransferase increased, bruising,
bleeding and increased blood pressure. Other common adverse drug reactions
(incidence 1 to 10%) are herpes zoster, weight gain, flatulence and
tuberculosis (1%).

About Tasigna

TASIGNA^® (nilotinib) is approved for the treatment of adult patients with
newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+
CML) in chronic phase. The effectiveness of TASIGNA for this indication is
based on major molecular response and cytogenetic response rates at 12 months.
The study is ongoing and further data will be required to determine long-term
outcome.

TASIGNA is also approved in more than 90 countries for the treatment of
chronic phase and accelerated phase Ph+ CML in adult patients resistant or
intolerant to at least one prior therapy, including Gleevec. The effectiveness
of TASIGNA for this indication is based on hematologic and cytogenetic
response rates.

BOXED WARNING and Important Safety Information for TASIGNA (nilotinib):

WARNING: QT PROLONGATION AND SUDDEN DEATHS

TASIGNA prolongs the QT interval. Prior to TASIGNA administration and
periodically, monitor for hypokalemia or hypomagnesemia and correct
deficiencies. Obtain ECGs to monitor the QTc at baseline, seven days after
initiation, and periodically thereafter, and follow any dose adjustments.

Sudden deaths have been reported in patients receiving nilotinib. Do not
administer TASIGNA to patients with hypokalemia, hypomagnesemia, or long QT
syndrome.

Avoid use of concomitant drugs known to prolong the QT interval and strong
CYP3A4 inhibitors.

Patients should avoid food 2 hours before and 1 hour after taking dose.

Treatment with TASIGNA can cause Grade 3/4 thrombocytopenia, neutropenia, and
anemia. Complete blood counts should be performed every 2 weeks for the first
2 months and then monthly thereafter.

Caution is recommended in patients with a history of pancreatitis.

The use of TASIGNA may result in elevations in bilirubin, AST/ALT, and
alkaline phosphatase.

TASIGNA can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia,
and hyponatremia (see Boxed WARNING).

The concomitant use of strong CYP3A4 inhibitors or anti-arrhythmic drugs
(including, but not limited to, amiodarone, disopyramide, procainamide,
quinidine, and sotalol) and other drugs that may prolong the QT interval
(including, but not limited to, chloroquine, clarithromycin, haloperidol,
methadone, moxifloxacin, and pimozide) should be avoided. Grapefruit products
should also be avoided.

The concomitant use of strong CYP3A4 inducers should be avoided (including,
but not limited to, dexamethasone, phenytoin, carbamazepine, rifampin,
rifabutin, rifapentin, phenobarbital, and St. John's wort).

TASIGNA must not be taken with food.

TASIGNA exposure is increased in patients with impaired hepatic function.

Cases of tumor lysis syndrome have been reported in TASIGNA treated patients
with resistant or intolerant CML. Due to potential for tumor lysis syndrome,
maintain adequate hydration and correct uric acid levels prior to initiating
therapy with TASIGNA.

The exposure of TASIGNA is reduced in patients with total gastrectomy.

Since the capsules contain lactose, TASIGNA is not recommended for patients
with rare hereditary problems of galactose intolerance, severe lactase
deficiency with a severe degree of intolerance to lactose-containing products,
or of glucose-galactose malabsorption.

Women of childbearing potential should avoid becoming pregnant while taking
TASIGNA and should be advised of the potential hazard to the fetus if they do.
The safety and effectiveness of TASIGNA in pediatric patients have not been
established.

In newly diagnosed Ph+ CML-chronic phase, the most commonly reported
nonhematologic adverse drug reactions (>10%) were rash, pruritus, headache,
nausea, fatigue, and myalgia.

In resistant or intolerant Ph+ CML-chronic phase, the most commonly reported
nonhematologic adverse drug reactions (greater than or equal to 10%) were
rash, pruritus, nausea, fatigue, headache, constipation, diarrhea, vomiting,
and myalgia.

In resistant or intolerant Ph+ CML-accelerated phase, the most commonly
reported nonhematologic adverse drug reactions (greater than or equal to 10%)
were rash, pruritus, and fatigue.

TASIGNA may need to be temporarily withheld and/or dose reduced for QT
prolongation, hematologic toxicities that are not related to underlying
leukemia, clinically significant moderate or severe nonhematologic toxicities,
laboratory abnormalities, or concomitant use of strong CYP3A4 inhibitors.

Please see full Prescribing Information including Boxed Warning.

About Gleevec

Gleevec^® (imatinib mesylate) tablets are indicated for newly diagnosed adult
patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+
CML) in the chronic phase (CP). Gleevec is also indicated for the treatment of
patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in CP
after failure of interferon-alpha therapy.

GLEEVEC^® Important Safety Information

GLEEVEC can cause fetal harm when administered to a pregnant woman. Women
should not become pregnant, and should be advised of the potential risk to the
unborn child.

GLEEVEC is often associated with edema (swelling) and serious fluid retention.
Studies have shown that edema (swelling) tended to occur more often among
patients who are 65 and older or those taking higher doses of GLEEVEC.

Cytopenias (reduction or lack of certain cell elements in blood circulation),
such as anemia, have occurred. If the cytopenia is severe, your doctor may
reduce your dose or temporarily stop your treatment with GLEEVEC.

Severe congestive heart failure and left ventricle dysfunction have been
reported, particularly in patients with other health issues and risk factors.
Patients with heart disease or risk factors or history of renal failure will
be monitored and treated for the condition.

Severe liver problems (hepatotoxicity) may occur. Cases of fatal liver failure
and severe liver injury requiring liver transplants have been reported with
both short-term and long-term use of GLEEVEC.

Bleeding may occur. Severe gastrointestinal (GI) bleeding has been reported in
patients with KIT+ GIST. GI tumor sites may be the cause of this bleeding;
therefore, GI symptoms should be monitored at the start of treatment.

In patients with hypereosinophilic syndrome (a condition with increased
eosinophils, which are a type of white blood cell) and heart involvement,
cases of heart disease (cardiogenic shock/left ventricular dysfunction) have
been associated with the initiation of GLEEVEC therapy.

Skin reactions, such as fluid-filled blisters, have been reported with the use
of GLEEVEC.

Clinical cases of hypothyroidism (reduction in thyroid hormones) have been
reported in patients taking levothyroxine replacement with GLEEVEC.

Long-term use may result in potential liver, kidney, and/or heart toxicities;
immune system suppression may also result from long-term use.

GI perforation (small holes or tears in the walls of the stomach or
intestine), in some cases fatal, has been reported.

Growth retardation has been reported in children taking GLEEVEC. The long-term
effects of extended treatment with GLEEVEC on growth in children are unknown.

Cases of tumor lysis syndrome (TLS), which refers to a metabolic and
electrolyte disturbance caused by the breakdown of tumor cells, have been
reported and can be life-threatening in some cases. Correction of clinically
significant dehydration and treatment of high uric acid levels are recommended
prior to initiation of GLEEVEC.

Reports of motor vehicle accidents have been received in patients receiving
GLEEVEC. Caution patients about driving a car or operating machinery.

Almost all patients treated with GLEEVEC experience side effects at some time.
Some common side effects you may experience are fluid retention, muscle cramps
or pain and bone pain, abdominal pain, loss of appetite, vomiting, diarrhea,
decreased hemoglobin, abnormal bleeding, nausea, fatigue and rash.

GLEEVEC is sometimes associated with stomach or intestinal irritation. GLEEVEC
should be taken with food and a large glass of water to minimize this problem.
There have been rare reports, including deaths, of stomach or intestinal
perforation (a small hole or tear).

If you are experiencing any of the mentioned side effects, please be sure to
speak with your doctor immediately.

Do not take any other medications without talking to your doctor or pharmacist
first, including Tylenol^® (acetaminophen); herbal products (St. John's wort,
Hypericum perforatum); Coumadin^® (warfarin sodium); rifampin; erythromycin;
metoprolol; ketoconazole; and Dilantin^® (phenytoin). Taking these with
GLEEVEC may affect how they work, or affect how GLEEVEC works.

You should also tell your doctor if you are taking or plan to take iron
supplements. Patients should also avoid grapefruit juice and other foods that
may affect how GLEEVEC works.

Please see full Prescribing Information.

About Exjade

Exjade^® is an oral iron chelation therapy indicated for the treatment of
chronic iron overload due to blood transfusions in adult and pediatric
patients (aged 2 years and over). It is approved in more than 100 countries
including the US, Switzerland, Japan and the countries comprising the EU. The
approved indication may vary depending upon the individual country.

Exjade^® Important Safety Information

Exjade is contraindicated in patients with creatinine clearance <40 mL/min or
serum creatinine >2 times the age-appropriate upper limit of normal; poor
performance status and high-risk myelodysplastic syndromes or advanced
malignancies: platelet counts <50 x 109/L; known hypersensitivity to
deferasirox or any component of Exjade.

There have been postmarketing reports of acute renal failure, hepatic failure
and cytopenias. Renal failure requiring temporary or permanent dialysis, renal
tubulopathy and interstitial nephritis have been reported. Upper
gastrointestinal ulceration and hemorrhage, sometimes fatal, have been
reported. Caution should be used in elderly patients due to a higher frequency
of adverse reactions. Exjade is not recommended in patients with a short life
expectancy (e.g., high-risk myelodysplastic syndromes), especially when
co-morbidities could increase the risk of adverse events.

Skin rashes, serious hypersensitivity reactions, decreased hearing and lens
opacities have been reported. The most common adverse reactions are nausea,
vomiting, diarrhea, abdominal pain, rash, non‐progressive increases in serum
creatinine, increased transaminases, abdominal distension, constipation,
dyspepsia, proteinuria and headache.

Please visit www.exjade.com. The full prescribing information including the
Boxed Warning for Exjade is available at
http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf.

About Afinitor (everolimus)

Afinitor^® (everolimus) is approved in the United States for the treatment of
postmenopausal women with advanced hormone receptor-positive, HER2-negative
breast cancer in combination with exemestane after failure of treatment with
letrozole or anastrozole.

For more information visit www.AFINITOR.com or call 1-888-4-AFINITOR. US
patients who may be eligible for financial assistance can learn about the
Novartis Patient Assistance Now Oncology (PANO) reimbursement support program
by contacting 1-800-282-7630 or visiting the Afinitor website.

In the United States, Afinitor tablets is approved for the treatment of adult
patients with advanced renal cell carcinoma after failure of treatment with
sunitinib or sorafenib and for the treatment of progressive neuroendocrine
tumors of pancreatic origin in adult patients with unresectable, locally
advanced or metastatic disease. The US Food and Drug Administration (FDA)
determined that the safety and effectiveness of Afinitor in the treatment of
patients with carcinoid tumors have not been established.

Afinitor is approved for the treatment of adult patients with renal
angiomyolipomas and tuberous sclerosis complex (TSC), who do not require
immediate surgery. The effectiveness of Afinitor in treatment of renal
angiomyolipoma is based on an analysis of durable objective responses in
patients treated for a median of 8.3 months. Further follow-up of patients is
required to determine long-term outcomes. In addition, Afinitor and Afinitor
Disperz™ are approved in the United States in pediatric and adult patients
with TSC for the treatment of subependymal giant cell astrocytoma (SEGA) that
requires therapeutic intervention but cannot be curatively resected.
Effectiveness is based on demonstration of durable objective response, as
evidenced by reduction in SEGA tumor volume. Improvement in disease-related
symptoms and overall survival in patients with SEGA and TSC have not been
demonstrated.

In the United States, Afinitor is available from Novartis in different dosage
strengths and for different uses in non-oncology patient populations under the
trade name Zortress^®. Everolimus is exclusively licensed to Abbott and
sublicensed to Boston Scientific for use in drug-eluting stents.

Not all indications are available in every country. Access to Afinitor outside
of the approved indications has been carefully controlled and monitored in
clinical trials designed to better understand the potential benefits and risks
of the compound. As an investigational compound, the safety and efficacy
profile of Afinitor has not yet been established outside the approved
indications. Because of the uncertainty of clinical trials, there is no
guarantee that Afinitor will become commercially available for additional
indications anywhere else in the world.

Afinitor^® Important Safety Information

Patients should not take Afinitor or Afinitor Disperz if they are allergic to
Afinitor or Afinitor Disperz or to any of its ingredients. Patients should
tell their healthcare provider before taking Afinitor or Afinitor Disperz if
they are allergic to sirolimus (Rapamune^®) or temsirolimus (Torisel^®).

Afinitor or Afinitor Disperz can cause serious side effects, including lung or
breathing problems, infections, and kidney failure, which can even lead to
death. If patients experience these side effects, they may need to stop taking
Afinitor or Afinitor Disperz for a while or use a lower dose. Patients should
follow their healthcare provider's instructions.

In some patients, lung or breathing problems may be severe and can even lead
to death. Patients should tell their healthcare provider right away if they
have any of these symptoms: new or worsening cough, shortness of breath, chest
pain, difficulty breathing, or wheezing.

Afinitor or Afinitor Disperz may make patients more likely to develop an
infection, such as pneumonia, or a bacterial, fungal, or viral infection.
Viral infections may include reactivation of hepatitis B in people who have
had hepatitis B in the past. In some people these infections may be severe and
can even lead to death. Patients may need to be treated as soon as possible.
Patients should tell their healthcare provider right away if they have a
temperature of 100.5˚F or above, chills, or do not feel well. Symptoms of
hepatitis B or infection may include the following: fever, chills, skin rash,
joint pain and inflammation, tiredness, loss of appetite, nausea, pale stools
or dark urine, yellowing of the skin, or pain in the upper right side of the
stomach.

Afinitor or Afinitor Disperz may cause kidney failure. In some people this may
be severe and can even lead to death. Patients should have tests to check
their kidney function before and during their treatment with Afinitor or
Afinitor Disperz.

Common side effects include mouth ulcers. Afinitor or Afinitor Disperz can
cause mouth ulcers and sores. Other common side effects include infections,
feeling weak or tired, nausea and vomiting, skin problems, headache, weight
loss, loss of appetite, cough, diarrhea, fever, swelling of the hands, arms,
legs, feet, face, or other parts of the body, joint pain, abnormal taste,
stomach-area (abdomen) pain, nose bleeds, seizure, increased blood cholesterol
and sugar levels, decreased blood phosphate levels, low red and white blood
cells, and the absence of menstrual periods (menstruation).

Please see full Prescribing Information for AFINITOR and AFINITOR DISPERZ
available at AFINITOR.com.

About CTL019, PKC412, LBH589 and BKM120

Because these are investigational compounds, the safety and efficacy profile
of CTL019, PKC412, LBH589 and BKM120 have not yet been established. Access to
these investigational compounds is available only through carefully controlled
and monitored clinical trials. These trials are designed to better understand
the potential benefits and risks of the compound. Because of uncertainty of
clinical trials, there is no guarantee that CTL019, PKC412, LBH589 and BKM120
will ever be commercially available anywhere in the world.

Disclaimer

The foregoing release contains forward-looking statements that can be
identified by terminology such as "pipeline," "ongoing," "commitment," "will,"
"expects," "could," "committed," "potential," "exploration," "explores," or
similar expressions, or by express or implied discussions regarding potential
marketing submissions or approvals for investigational compounds, or potential
new indications or labeling for existing products, or regarding potential
future revenues from such products. You should not place undue reliance on
these statements. Such forward-looking statements reflect the current views of
management regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially
different from any future results, performance or achievements expressed or
implied by such statements. There can be no guarantee that any of the
investigational compounds referred to in this release will be submitted or
approved for sale in any market, or at any particular time. Nor can there be
any guarantee that any of the approved products referred to in this release
will be submitted or approved for any additional indications or labeling in
any market, or at any particular time. Neither can there be any guarantee that
any of the investigational compounds or products referred to in this release
will achieve any particular levels of revenue in the future. In particular,
management's expectations regarding such products could be affected by, among
other things, unexpected clinical trial results, including unexpected new
clinical data and unexpected additional analysis of existing clinical data;
unexpected regulatory actions or delays or government regulation generally;
competition in general; government, industry and general public pricing
pressures; the company's ability to obtain or maintain patent or other
proprietary intellectual property protection; unexpected manufacturing issues;
the impact that the foregoing factors could have on the values attributed to
the Novartis Group's assets and liabilities as recorded in the Group's
consolidated balance sheet, and other risks and factors referred to in
Novartis AG's current Form 20-F on file with the US Securities and Exchange
Commission. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary
materially from those anticipated, believed, estimated or expected. Novartis
is providing the information in this press release as of this date and does
not undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information, future events
or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and
markets innovative prescription drugs used to treat a number of diseases and
conditions, including cardiovascular, dermatological, central nervous system,
bone disease, cancer, organ transplantation, psychiatry, infectious disease
and respiratory. The company's mission is to improve people's lives by
pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is
an affiliate of Novartis AG, which provides innovative healthcare solutions
that address the evolving needs of patients and societies. Headquartered in
Basel, Switzerland, Novartis offers a diversified portfolio to best meet these
needs: innovative medicines, eye care, cost-saving generic pharmaceuticals,
preventive vaccines and diagnostic tools, over-the-counter and animal health
products. Novartis is the only global company with leading positions in these
areas. In 2011, the Group's continuing operations achieved net sales of USD
58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding
impairment and amortization charges) was invested in R&D throughout the Group.
Novartis Group companies employ approximately 127,000 full-time-equivalent
associates and operate in more than 140 countries around the world. For more
information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at
http://twitter.com/novartis.

^* Known as Glivec^® (imatinib) outside the US, Canada and Israel.
^† CTL019 is developed in collaboration with the University of Pennsylvania.

References

1. American Society of Hematology. ASH Annual 2012 Meeting Program. Available
at https://ash.confex.com/ash/2012/webprogram/start.html. Accessed November
2012.

2. San Antonio Breast Cancer Symposium. SABCS Annual 2012 Meeting Program.
Available at http://www.sabcs.org/ProgramSchedule/index.asp. Accessed November
2012.

3. JAKAVI [Summary of Product Characteristics]. Basel, Switzerland: Novartis
Pharma AG; 2012.

Novartis Media Relations
Julie Masow
                                       Gloria Vanderham
Novartis Corporation
                                       Novartis Oncology
+1 212 830 2465 (direct)
                                       +1 862 778 4268 (direct)
+1 862 579 8456 (mobile)
                                       +1 862 926 8420 (mobile)
julie.masow@novartis.com
                                       gloria.vanderham@novartis.com
e-mail: us.mediarelations@novartis.com

For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis.
For questions about the site or required registration, please contact:
journalisthelp@thenewsmarket.com.

SOURCE Novartis

Website: http://www.novartis.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement